65,437 trials
Bone Cancer · Chondrosarcoma · Clear Cell Sarcoma of the Kidney
Primary: Antitumor Activity as Assessed by Number of Patients Showing an Objective Tumor Response — 0 participants
Cardiac Edema
Primary: Body Weight — -2.05; -1.31; -2.9 Kg
Myeloproliferative Disorders
Primary: Participants With an Objective Response — 0; 0; 2 Participants
Smoking Dependence · Smoking
Primary: Change From Post-cue Baseline in Nicotine Craving Score at 5 Minutes — -41.8; -25.9 Score on a scale — p=<0.0001
Coronary Artery Bypass Grafting · Heart Valve Surgery
Primary: Peri- and Postoperative Time Course of Circulating 1,25-dihydroxyvitamin D in the First Postoperative Month in Cardiac Surgery Patients — 13; 4.2 percentage
Pain Due to Osteoporosis
Primary: Pain (Subjective Symptom) — -37.8; -24.5; -40.5; -29.0 mm
Anemia · Non-Myeloid Malignancies
Primary: Number of Participants Who Achieved the Target Hemoglobin Level, by Darbepoetin Alfa Dose — 71; 82 Participants
Human Influenza
Primary: Percentage of Subjects Who Achieved Seroconversion or Significant Increase in SRH Area Against Each of Three Vaccine Strains After One Vaccination of TIV — 84; 53; 81…
Extrahepatic Bile Duct Adenocarcinoma · Gallbladder Adenocarcinoma · Gallbladder Adenocarcinoma With Squamous Metaplasia
Primary: Progression-free Survival — 2 months
Healthy Males
Primary: Intratesticular Testosterone (IT-T) Level — 14; 3.7; 1.7; 18.4 ng/mL — p=<0.05
Acute Gouty Arthritis
Primary: Pain Intensity on a 0-100 mm Visual Analog Scale (VAS) Between the Canakinumab 150 mg PFS and Triamcinolone Acetonide 40 mg Groups — 17.1; 32 Millimeters
Atherosclerosis · Cardiovascular Diseases · Hypertension, Renovascular
Primary: Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent…
Cocaine Dependence
Primary: Percent of Participants Reporting no Cocaine Craving — 64; 41 Percent of participants
Arrhythmias, Cardiac
Primary: Cumulative Dose Area Product (DAP) Value — 8.8; 15.3 Gy*cm^2 — p=<0.0001
Ototoxicity · Unspecified Adult Solid Tumor
Primary: Ototoxicity Measurement — 7; 7 participants — p=0.89